Closed · W81XWH-15-DMRDP-CRMRP-ERTTDA · CFDA 12.420 · Discretionary

DoD FY15 Extremity Regeneration Technology/Therapeutic Development Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
December 22, 2015
Close date
3
Expected awards

The verdict

DoD FY15 Extremity Regeneration Technology/Therapeutic Development Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 3 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
3
expected awards
12.420
CFDA program

Archived opportunity record

DoD FY15 Extremity Regeneration Technology/Th… is closed (last close December 22, 2015). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed December 22, 2015

Posted Oct 14 Closes Dec 22

Est. Total Funding

$6,300,000

Expected Awards

3

Instrument

Grant

Description

The Fiscal Year 2015 (FY15) Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) Extremity Regeneration Technology/Therapeutic Development Award (ERTTDA) is intended to support the translation of promising preclinical findings into products focused on extremity regeneration. The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage. All products in development should be responsive to the health care needs of military Service members, Veterans, and other Military Health System beneficiaries, as well as the general public. All applications must specifically and clearly address the military relevance of the proposed research.The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product such as clinical guidance for standard of care. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the award.Proof-of-concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. Applicants must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.Examples of the types of research that may be supported include, but are not limited to: Developing and validating clinical guidance/guidelines for standard of care; Testing new therapeutic modalities (agents, delivery systems, and chemical modification of lead compounds) using established or validated preclinical systems; Designing and implementing pilot or full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials; Developing pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies;Developing pharmacologic agents to Investigational New Drug (IND) stage for initiation of Phase I clinical trials; Developing prototype devices to Investigational Device Exemption (IDE) stage for initiation of clinical trials; Optimizing diagnostic or treatment devices for field deploymentTo meet the intent of the FY15 JPC-8/CRMRP ERTTDA, applicants must specifically address one or both of the Focus Areas listed below; (1) Treatments of soft tissue injury, specifically, nerve, muscle, and vascular injury to the extremities. The aim of these technologies is to: (a) maintain the structure and function of denervated end organs distal to a nerve injury; (b) restore functional muscle tissue; and (c) restore vascular perfusion. Both innovative definitive care solutions as well as innovative technologies that may better enable a definitive care solution to be delivered at some future time point, such as vascular shunting or stenting technologies, will be considered; (2) Treatments for bone healing, for example, technologies that create a wound environment more conducive to bone healing following injury to the extremities.

Catch-all / unrestricted eligibility mark · W81XWH-15-DMRDP-CRMRP-ERTTDA

Grants.gov marks DoD FY15 Extremity Regeneration Technology/Th… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk 301-682-5507 help@eBRAP.org

What to do next

DoD FY15 Extremity Regeneration Technology/Th… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants